GLP-1 + GIP: A Powerful Combination Some newer medications, like tirzepatide, combine GLP-1 with another hormone called GIP (glucose-dependent insulinotropic polypeptide)
This effect was abolished by an inhibitor of NOS, suggesting the activation of eNOS by exendin-4 [90]
GLP-1 receptor agonists should not be co-prescribed with DPP-4 inhibitors, as this combination is not recommended in UK practice
A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful weight loss while simultaneously protecting the heart, kidneys, and metabolic health
Address gastrointestinal symptoms proactively to prevent dehydration
Diabetes, Obesity and Metabolism, 2023